In our present analysis of 31 triple-negative breast cancers, the DFS of patients with CA9-positive tumors was significantly shorter (p = 0.015) than that of patients with CA9-negative tumors (Additional file 2: Figure S1). This evidence concerns the gene CA9 and triple-negative breast carcinoma.